Johnson & Johnson's earnings call highlighted strong performance, with operational sales growth and increased EPS exceeding expectations.  Management expressed confidence in meeting, and potentially exceeding, 2023 guidance, citing strong pipeline progress and favorable market conditions.  While the talc litigation remains a concern, the projected trajectory and positive guidance are likely to propel the stock price upwards in the next few weeks.
[2]
